Marcus Schmidt
Impact in
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
Papers in
-
- Breast Cancer Treatment Studies 80
- Oncology 125
- HER2/EGFR in Cancer Research 53
- Cancer Treatment and Pharmacology 31
- Cancer Immunotherapy and Biomarkers 18
- Cancer Cells and Metastasis 16
- Co-authors
- Jan Georg Hengstler (37 shared papers)Mathias C. Gehrmann (22 shared papers)Johannes Ettl (3 shared papers)Ravindranath Patel (4 shared papers)Richard S. Finn (3 shared papers)Katalin Boér (4 shared papers)Xin Huang (3 shared papers)Tamás Pintér (4 shared papers)
- Journals
- Breast Care (34 papers)Annals of Oncology (17 papers)Breast Cancer Research and Treatment (14 papers)Journal of Cancer Research and Clinical Oncology (13 papers)European Journal of Cancer (12 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Marcus Schmidt
307 papers receiving 15.2k citations
Marcus Schmidt's Hit Papers
Peers
Comparison fields: 5 of 170
- Cancer Research 4.0k
- Oncology 7.0k
- Pulmonary and Respiratory Medicine 3.6k
- Immunology 1.3k
- Genetics 616
Countries citing papers authored by Marcus Schmidt
This map shows the geographic impact of Marcus Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Schmidt more than expected).
Fields of papers citing papers by Marcus Schmidt
This network shows the impact of papers produced by Marcus Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Schmidt. The network helps show where Marcus Schmidt may publish in the future.
Co-authors
The 25 scholars most cited alongside Marcus Schmidt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 318 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Hit paper breakdown → | 2014 | 1590 |
| 2 | Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Hit paper breakdown → | 2014 | 868 |
| 3 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 668 |
| 4 | 2008 | 641 | |
| 5 | Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer Hit paper breakdown → | 2021 | 581 |
| 6 | 2009 | 567 | |
| 7 | 2011 | 555 | |
| 8 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 9 | Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Hit paper breakdown → | 2021 | 409 |
| 10 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 321 |
| 11 | 2011 | 282 | |
| 12 | 2013 | 266 | |
| 13 | 2001 | 211 | |
| 14 | 2000 | 196 | |
| 15 | 2012 | 192 | |
| 16 | 2014 | 167 | |
| 17 | 2010 | 167 | |
| 18 | 2012 | 153 | |
| 19 | 2016 | 152 | |
| 20 | 2011 | 152 |
About Marcus Schmidt
Marcus Schmidt is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Obstetrics and Gynecology, having authored 318 papers that have together received 15.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (80 papers), HER2/EGFR in Cancer Research (53 papers), Advanced Breast Cancer Therapies (45 papers), Cancer Treatment and Pharmacology (31 papers), Cancer Immunotherapy and Biomarkers (18 papers), Breast Lesions and Carcinomas (17 papers), Cancer Cells and Metastasis (16 papers) and Immunotherapy and Immune Responses (11 papers). The work is most often cited by research in Cancer Research (4.0k citations), Oncology (7.0k citations), Pulmonary and Respiratory Medicine (3.6k citations), Immunology (1.3k citations) and Genetics (616 citations). Marcus Schmidt has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Jan Georg Hengstler, Mathias C. Gehrmann, Johannes Ettl, Ravindranath Patel, Richard S. Finn, Katalin Boér, Xin Huang, Tamás Pintér, Dennis J. Slamon and Sophia Randolph. Their work appears in journals such as Breast Care, Annals of Oncology, Breast Cancer Research and Treatment, Journal of Cancer Research and Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.